FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2955594328> ?p ?o ?g. }

• W2955594328 endingPage "232" @default.
• W2955594328 startingPage "226" @default.
• W2955594328 abstract "In 2017, the Canadian Association of Radiologists issued a clinical practice guideline (CPG) regarding the use of gadolinium-based contrast agents (GBCAs) in patients with acute kidney injury (AKI), chronic kidney disease (CKD), or on dialysis due to mounting evidence indicating that nephrogenic systemic fibrosis (NSF) occurs with extreme rarity or not at all when using Group II GBCAs or the Group III GBCA gadoxetic acid (compared to first generation Group I linear GBCAs). One of the goals of the work group was to re-evaluate the CPG after 24 months to determine the effect of more liberal use of GBCA on reported cases of NSF in patients with AKI, CKD Stage 4 or 5 (estimated glomerular filtration rate [eGFR] < 30 mL/min/1.73 m2), or those that are dialysis-dependent. A comprehensive review of the literature was conducted by a subcommittee of the initial CPG panel between the dates of January 1, 2017-December 31, 2018 to identify new unconfounded cases of NSF linked to Group II or Group III GBCAs and an updated CPG developed. To our knowledge, when using a Group II or Group III GBCA between 2017-2018, only a single unconfounded case report of a fibrosing dermopathy has been reported in a patient who received gadobenate dimeglumine with Stage 2 CKD. No other unconfounded cases of NSF have been reported with Group II or III agents in during this timeframe. The subcommittee concluded that the main recommendations from the 2017 CPG should remain unaltered, but agreed that screening for renal disease in the outpatient setting is no longer justifiable, cost-effective or recommended. Patients on hemodialysis (HD) should, however, be identified prior to GBCA administration to arrange timely HD to optimize gadolinium clearance, although there remains no evidence that HD reduces the risk of NSF. When administering Group II or III GBCAs to patients with AKI, on dialysis or with severe CKD, informed consent relating to NSF is also no longer explicitly recommended." @default.
• W2955594328 created "2019-07-12" @default.
• W2955594328 creator A5013058267 @default.
• W2955594328 creator A5016002613 @default.
• W2955594328 creator A5023257162 @default.
• W2955594328 creator A5040148417 @default.
• W2955594328 creator A5052698921 @default.
• W2955594328 date "2019-08-01" @default.
• W2955594328 modified "2023-10-14" @default.
• W2955594328 title "Updated Clinical Practice Guideline on Use of Gadolinium-Based Contrast Agents in Kidney Disease Issued by the Canadian Association of Radiologists" @default.
• W2955594328 cites W1937021802 @default.
• W2955594328 cites W1965729533 @default.
• W2955594328 cites W1983147028 @default.
• W2955594328 cites W1984468396 @default.
• W2955594328 cites W1999260980 @default.
• W2955594328 cites W1999890744 @default.
• W2955594328 cites W2005973008 @default.
• W2955594328 cites W2010682958 @default.
• W2955594328 cites W2021130244 @default.
• W2955594328 cites W2031557262 @default.
• W2955594328 cites W2040865649 @default.
• W2955594328 cites W2047961324 @default.
• W2955594328 cites W2051298395 @default.
• W2955594328 cites W2051466008 @default.
• W2955594328 cites W2053564324 @default.
• W2955594328 cites W2053929381 @default.
• W2955594328 cites W2059283030 @default.
• W2955594328 cites W2062381788 @default.
• W2955594328 cites W2106735378 @default.
• W2955594328 cites W2122855609 @default.
• W2955594328 cites W2152073293 @default.
• W2955594328 cites W2172097293 @default.
• W2955594328 cites W2239098777 @default.
• W2955594328 cites W2312877362 @default.
• W2955594328 cites W2460505725 @default.
• W2955594328 cites W2605169844 @default.
• W2955594328 cites W2777301039 @default.
• W2955594328 cites W2801940029 @default.
• W2955594328 cites W2802352705 @default.
• W2955594328 cites W2808380430 @default.
• W2955594328 cites W2890242827 @default.
• W2955594328 cites W2891480757 @default.
• W2955594328 cites W2905454744 @default.
• W2955594328 cites W4242894962 @default.
• W2955594328 doi "https://doi.org/10.1016/j.carj.2019.04.001" @default.
• W2955594328 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31255393" @default.
• W2955594328 hasPublicationYear "2019" @default.
• W2955594328 type Work @default.
• W2955594328 sameAs 2955594328 @default.
• W2955594328 citedByCount "45" @default.
• W2955594328 countsByYear W29555943282019 @default.
• W2955594328 countsByYear W29555943282020 @default.
• W2955594328 countsByYear W29555943282021 @default.
• W2955594328 countsByYear W29555943282022 @default.
• W2955594328 countsByYear W29555943282023 @default.
• W2955594328 crossrefType "journal-article" @default.
• W2955594328 hasAuthorship W2955594328A5013058267 @default.
• W2955594328 hasAuthorship W2955594328A5016002613 @default.
• W2955594328 hasAuthorship W2955594328A5023257162 @default.
• W2955594328 hasAuthorship W2955594328A5040148417 @default.
• W2955594328 hasAuthorship W2955594328A5052698921 @default.
• W2955594328 hasBestOaLocation W29555943281 @default.
• W2955594328 hasConcept C126322002 @default.
• W2955594328 hasConcept C126838900 @default.
• W2955594328 hasConcept C142724271 @default.
• W2955594328 hasConcept C146357865 @default.
• W2955594328 hasConcept C151730666 @default.
• W2955594328 hasConcept C159641895 @default.
• W2955594328 hasConcept C177713679 @default.
• W2955594328 hasConcept C1862650 @default.
• W2955594328 hasConcept C2778653478 @default.
• W2955594328 hasConcept C2779974597 @default.
• W2955594328 hasConcept C2779978075 @default.
• W2955594328 hasConcept C2780182762 @default.
• W2955594328 hasConcept C2780472472 @default.
• W2955594328 hasConcept C2781027423 @default.
• W2955594328 hasConcept C71924100 @default.
• W2955594328 hasConcept C86803240 @default.
• W2955594328 hasConceptScore W2955594328C126322002 @default.
• W2955594328 hasConceptScore W2955594328C126838900 @default.
• W2955594328 hasConceptScore W2955594328C142724271 @default.
• W2955594328 hasConceptScore W2955594328C146357865 @default.
• W2955594328 hasConceptScore W2955594328C151730666 @default.
• W2955594328 hasConceptScore W2955594328C159641895 @default.
• W2955594328 hasConceptScore W2955594328C177713679 @default.
• W2955594328 hasConceptScore W2955594328C1862650 @default.
• W2955594328 hasConceptScore W2955594328C2778653478 @default.
• W2955594328 hasConceptScore W2955594328C2779974597 @default.
• W2955594328 hasConceptScore W2955594328C2779978075 @default.
• W2955594328 hasConceptScore W2955594328C2780182762 @default.
• W2955594328 hasConceptScore W2955594328C2780472472 @default.
• W2955594328 hasConceptScore W2955594328C2781027423 @default.
• W2955594328 hasConceptScore W2955594328C71924100 @default.
• W2955594328 hasConceptScore W2955594328C86803240 @default.
• W2955594328 hasIssue "3" @default.
• W2955594328 hasLocation W29555943281 @default.
• W2955594328 hasLocation W29555943282 @default.
• W2955594328 hasOpenAccess W2955594328 @default.

• next